OnCo
trialsTrialPlanned

Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing

A phase 3 trial of Guardant Reveal in Breast cancer, run by SWOG Cancer Research Network, not yet recruiting.